Ruben Magni serves as a Principal Scientist in Analytical Development at Clasp Therapeutics, where he leverages over 15 years of extensive experience in analytical chemistry to drive the advancement of innovative biotherapeutics. His expertise encompasses a wide range of analytical techniques, including mass spectrometry, chromatography,...
Ruben Magni serves as a Principal Scientist in Analytical Development at Clasp Therapeutics, where he leverages over 15 years of extensive experience in analytical chemistry to drive the advancement of innovative biotherapeutics. His expertise encompasses a wide range of analytical techniques, including mass spectrometry, chromatography, and immunoassays, which are critical in the development of complex biologics such as protein vaccines and bispecific antibodies. At Clasp Therapeutics, Ruben has been instrumental in the development and execution of analytical assays that assess the purity, potency, and stability of these biologics, ensuring they meet stringent regulatory standards.
Ruben's current projects involve the characterization and quality assessment of bispecific antibodies, utilizing advanced methodologies such as reverse-phase chromatography (RP), high-performance liquid chromatography (HIC), size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS), and capillary electrophoresis (CE-SDS). His proficiency in charge variant analysis and physicochemical testing plays a pivotal role in optimizing formulation development and conducting stability studies, which are essential for successful drug development.
In addition to his technical skills, Ruben excels in project management and adheres to Good Manufacturing Practice (GMP) and Clinical Laboratory Improvement Amendments (CLIA) standards, ensuring that all analytical processes are compliant and efficient. His ability to communicate complex scientific concepts clearly and effectively enhances collaboration across multidisciplinary teams, fostering a culture of innovation and excellence at Clasp Therapeutics. As he continues to contribute to the field of biotherapeutics, Ruben remains dedicated to advancing the science of drug development and biomarker discovery, ultimately aiming to improve patient outcomes through cutting-edge therapeutic solutions.
